Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitlePaclitaxel, Not Bevacizumab, Was Primarily Responsible for the Favorable Effects Seen in the RIBBON-2 Trial.AuthorsKesikli, Altug; Kilickap, Saadettin; Brufsky, Adam M.PublicationJournal of Clinical Oncology, 2012, Vol 30, Issue 4, p461ISSN0732-183xPublication typearticleDOI10.1200/JCO.2011.40.2305